GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
New York, NY, November 30, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing
New York, NY, November 30, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing
Clinical Validation Study Results for SARS CoV2 Ab Test. Evaluating site locations for build out of high-tech manufacturing facility supported
Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility. Signs Strategic Partnerships with Johns
In all target markets, 90% of patients responded positively to the Biosensor Platform technology. Seven out of 10 patients were
New York, NY, July 8, 2021 – GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for
Global results show 90% of patients are in favor of a saliva-based glucose test New York, NY, June 7, 2021
Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021. $14 Million in Cash, Cash
NEW YORK APRIL 15, 2021 – GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests,
New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point
Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in
SYDNEY – May 6, 2020 The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd
SYDNEY – May 29, 2020 Life Science Biosensor Diagnostics Pty Ltd (LSBD), a development company of The iQ Group Global,
The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 – The iQ Group